HeartSciences Inc. (HSCS) Fair Value 2026

HSCS · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.9 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (44/100)

Quick Summary — As of 2026-08-28, HeartSciences Inc. (HSCS) trades at $3.03. QOC: 4.9/10. Value Trap Risk: 44/100 (WARN). 0/13 models active.

Key Facts

Ticker
HSCS
Price
$3.03
Quality Score
4.9/10
Value Trap Risk
44/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 44 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give HSCS?

0 Intrinsic Value Models vs. Current Price ($3.03)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is HeartSciences Inc. (HSCS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, HeartSciences Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About HSCS?

0 of 13 models are currently active for HSCS. See which stocks rank higher →

How Does HSCS Rank in Medical Devices?

Among 159 Medical Devices stocks, HSCS ranks #127 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

As a biopharma enterprise, HeartSciences Inc. operates in a sector where clinical trial success rate is a critical driver of valuation. Investors evaluating HSCS should weigh these sector-specific dynamics alongside our model-derived fair values.

Is HSCS a Value Trap?

CirclFi's Value Trap algorithm assigns HSCS a score of 44/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for HeartSciences Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, HeartSciences Inc.'s fundamental quality profile registers 4.9/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HSCS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy HeartSciences Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

TNONTenon Medical, Inc.QOC 5.0MBOTMicrobot Medical Inc.QOC 4.9VTAKCatheter Precision, Inc.QOC 5.0FEEDENvue Medical, Inc.QOC 4.8VVOSVivos Therapeutics, Inc.QOC 5.0TRIBTrinity Biotech plcQOC 4.8ELMDElectromed, Inc.QOC 9.1LNSRLENSAR, Inc.QOC 7.1BBNXBeta Bionics, Inc.QOC 6.1IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: TNON · MBOT · VTAK · FEED · VVOS · TRIB · ELMD · LNSR · BBNX · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to HSCS?

7 companies across all industries closest to HSCS’s Quality of Company score of 4.9/10.

TOGITurnOnGreen, IncQOC 4.9IPSCCentury Therapeutics, Inc.QOC 4.9PSPershing Square Inc.QOC 4.9HQLAbrdn Life Sciences InvestorsQOC 4.9MRTMarti Technologies, Inc.QOC 5.0ARTVArtiva Biotherapeutics, Inc.QOC 4.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TOGI · IPSC · PS · HQL · MRT · ARTV · NVDA

Where Does HSCS Sit in CirclFi's Medical Devices Rankings?

HSCS is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About HeartSciences Inc.’s Valuation?

What is HeartSciences Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for HeartSciences Inc. (HSCS). The Quality of Company score is 4.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HSCS overvalued or undervalued right now?

At $3.03, 0 of 0 active models suggest HSCS may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits HeartSciences Inc.'s business model in Medical Devices.

What does a Quality of Company score of 4.9 mean for HSCS?

HeartSciences Inc.'s QOC of 4.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on HSCS?

CirclFi analyzes HSCS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is HSCS a value trap in 2026?

HeartSciences Inc.'s Value Trap score is 44/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns HeartSciences Inc. (HSCS) a Quality of Company score of 4.9/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/HSCS/ · Methodology
Primary sources for this HSCS valuation
  • Financial statements: HeartSciences Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001468492) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for HSCS as of ; valuations recomputed .